NCT04445610

Brief Summary

The following two mechanisms that explain the ability of measles vaccine to cause partial protection against COVID-19. The first is that measles vaccine may increase the ability of the immune system to fight off pathogens other than measles due to the generated bystander immunity that would enhance the overall immunity against the new coronavirus. The second is that SARS-CoV-2 is proven to have structure similarities with measles, which may cause cross-reactivity and immunity between measles vaccines and COVID-19, leading to partial protection against COVID-19 in vaccinated subjects

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 23, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 24, 2020

Completed
7 days until next milestone

Study Start

First participant enrolled

July 1, 2020

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2020

Completed
Last Updated

June 26, 2020

Status Verified

June 1, 2020

Enrollment Period

2 months

First QC Date

June 23, 2020

Last Update Submit

June 24, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Viral clearance

    Achievement of two consecutive negative PCR results for COVID 19 and discharge from hospital

    6 months

Study Arms (3)

A

mild

B

moderate

C

severe

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all patients with confirmed COVID-19 presented to Ain Shams Hospital

You may qualify if:

  • All patients with confirmed COVID 19.
  • Any age or gender

You may not qualify if:

  • \- Any patient refusing to be involved in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center

Cairo, Non-US, 11566, Egypt

Location

MeSH Terms

Conditions

Coronavirus InfectionsCOVID-19

Condition Hierarchy (Ancestors)

Coronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsVirus DiseasesInfectionsPneumonia, ViralPneumoniaRespiratory Tract InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Amira Al Balakosy, M.D

    Ain Shams University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Amira Al Balakosy, MD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Tropical Medicine Department. Ain Shams University

Study Record Dates

First Submitted

June 23, 2020

First Posted

June 24, 2020

Study Start

July 1, 2020

Primary Completion

September 1, 2020

Study Completion

November 1, 2020

Last Updated

June 26, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will not share

Locations